Core Viewpoint - Nuvalent, Inc. has announced a public offering of Class A common stock priced at $101.00 per share, aiming to raise approximately $500 million before expenses [1][2]. Group 1: Offering Details - The company is selling 4,950,496 shares in the offering, with the expected closing date on November 20, 2025, pending customary closing conditions [1]. - Selling stockholders have granted underwriters a 30-day option to purchase an additional 742,574 shares at the public offering price [2]. - J.P. Morgan, Jefferies, TD Cowen, and Cantor are acting as joint book-running managers for the offering [3]. Group 2: Regulatory Information - The shares are being offered under an automatically effective shelf registration statement filed with the SEC on March 16, 2023 [4]. - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus will also be filed [4]. Group 3: Company Overview - Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, particularly for kinase targets [6]. - The company aims to create innovative small molecules that can overcome resistance and minimize adverse events, with a pipeline targeting ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer [6].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Accessibility StatementSkip Navigation Company to host webcast and conference call on November 17, 2025 at 8:00am ET CAMBRIDGE, Mass., Nov. 14, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the company will host a webcast and conference call on Monday, November 17, 2025 at 8:00 a.m. ET, to discuss topline pivotal data for neladalkib, an inv ...